Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

Add GALT Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 3/25/2020 4:26:47 AM - Followers: 82 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:




Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.




Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT News: Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical Officer 02/20/2020 08:00:10 AM
GALT News: Current Report Filing (8-k) 02/20/2020 07:55:42 AM
GALT News: Statement of Changes in Beneficial Ownership (4) 02/14/2020 08:01:59 AM
GALT News: Annual Statement of Changes in Beneficial Ownership (5) 02/13/2020 05:00:59 PM
GALT News: Annual Statement of Changes in Beneficial Ownership (5) 02/13/2020 04:37:06 PM
#3670   Very few posts. Pretty sad the company Chess Master 03/25/20 04:26:47 AM
#3669   Any update on ph where you been Minitruckin 03/06/20 08:59:25 AM
#3668   Can you pm what you think phil expect Minitruckin 02/10/20 07:37:01 AM
#3667   Bucky, I hope you didn’t completely abandon CYDY. EponymousKook 12/17/19 07:26:55 PM
#3666   Once the correct number of patients reach 1 buckysherm 11/13/19 02:52:14 PM
#3665   So here is combo of bad news 1. The Amatuer17 11/12/19 05:44:23 PM
#3664   REALIZE FDA DELAY = VERY POSITIVE - We Chess Master 11/12/19 05:34:14 PM
#3663   WE LIKE THE CHARTS - Keep em coming Pennyzilla 11/12/19 05:14:24 PM
#3662   lol ClayTrader 11/12/19 04:43:39 PM
#3661   Typical short view point. Wish his self Chess Master 11/12/19 04:40:42 PM
#3660   I didn’t see another study for dosing. buckysherm 11/12/19 03:07:21 PM
#3659   Agree stock_observer_77 11/12/19 02:49:21 PM
#3658   And sometimes delay in news means serious delays. New Amatuer17 11/12/19 01:34:27 PM
#3657   FDA = Forking Delayed Again buckysherm 11/12/19 08:29:38 AM
#3656   Of course it doesn’t stock_observer_77 11/11/19 11:33:25 PM
#3655   Actually read the PR - the collaboration is Amatuer17 11/11/19 11:19:56 PM
#3654   * * $GALT Video Chart 11-11-19 * * ClayTrader 11/11/19 05:26:31 PM
#3653   As far as Siemens goes it looks like jimmy667 11/11/19 04:56:15 PM
#3652   News: $GALT Galectin Therapeutics Reaches Agreement with Siemens whytestocks 11/11/19 12:30:24 PM
#3651   Yeah, why would they agree to this BEFORE buckysherm 11/11/19 10:58:33 AM
#3650   I'm sure Siemens doesn't stock_observer_77 11/11/19 10:38:17 AM
#3649   Siemens think that too??? stock_observer_77 11/11/19 10:37:53 AM
#3648   That’s exactly what I thought. That’s exactly what buckysherm 11/11/19 10:19:23 AM
#3647   The delay in announcement seems to indicate that Amatuer17 11/09/19 06:35:35 PM
#3646   Sorry, 95 on Saturday. buckysherm 11/07/19 09:36:10 PM
#3645   85, 90 ... We have 85, 90 on buckysherm 11/07/19 09:34:00 PM
#3644   Good luck stock_observer_77 11/06/19 06:35:33 AM
#3643   Giving advice to sell is sign of cult Amatuer17 11/06/19 06:14:00 AM
#3642   You better sell stock_observer_77 11/06/19 06:00:19 AM
#3641   Very bad for the company - topline results announced Amatuer17 11/06/19 05:52:52 AM
#3640   80 days, do I hear 85 days ? buckysherm 11/04/19 06:31:20 PM
#3639   No update yet - crossed 75 days Amatuer17 10/30/19 05:07:54 PM
#3638   It’s public info - we will know stock_observer_77 10/24/19 03:06:15 AM
#3637   GALT doesn’t care whether we know about this buckysherm 10/23/19 11:17:03 PM
#3636   I believe a response is required by FDA stock_observer_77 10/22/19 09:04:31 PM
#3635   Is 75 days official guideline? Cannot find any documentation Amatuer17 10/22/19 08:51:16 PM
#3634   The 75 days are not up yet stock_observer_77 10/21/19 09:03:59 AM
#3633   These guidelines aren't 'favorable' at all for GALT biotech2010 10/21/19 08:42:50 AM
#3632   Is no one interested ? It appears buckysherm 10/15/19 12:05:56 AM
#3631   75 days would be .... tomorrow ? Sweet dreams. buckysherm 10/15/19 12:04:44 AM
#3630   Here are NASH-CX trial protocol guidelines for P3 Amatuer17 10/14/19 08:11:26 PM
#3629   Interesting report - out of $18 B potential Amatuer17 10/14/19 07:53:07 PM
#3628   The First step is the notice to proceed Chess Master 10/11/19 09:31:57 AM
#3627   I am hoping something like this deal - Amatuer17 10/07/19 01:30:18 PM
#3626   I got from the business update Galectin Therapeutics Reports Amatuer17 10/07/19 01:26:51 PM
#3625   I see no news to support a 9% jimmy667 10/07/19 12:23:24 PM
#3624   It looks like some are buying the rumour jimmy667 10/07/19 12:18:20 PM
#3623   The phase 3 protocol was submitted on Aug Amatuer17 10/02/19 04:39:47 PM
#3622   This is long term play if they go Amatuer17 09/13/19 05:12:49 AM
#3621   Test buckysherm 09/12/19 02:17:28 PM